Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.

Zeidan AM, Knaus HA, Robinson TM, Towlerton AMH, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD.

Clin Cancer Res. 2018 May 1. doi: 10.1158/1078-0432.CCR-17-3763. [Epub ahead of print]

PMID:
29716921
2.

Diagnostic utility of telomere length testing in a hospital-based setting.

Alder JK, Hanumanthu VS, Strong MA, DeZern AE, Stanley SE, Takemoto CM, Danilova L, Applegate CD, Bolton SG, Mohr DW, Brodsky RA, Casella JF, Greider CW, Jackson JB, Armanios M.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2358-E2365. doi: 10.1073/pnas.1720427115. Epub 2018 Feb 20. Erratum in: Proc Natl Acad Sci U S A. 2018 Apr 23;:.

3.

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.

Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2018 May;24(5):1099-1102. doi: 10.1016/j.bbmt.2018.02.005. Epub 2018 Feb 13.

PMID:
29452245
4.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

PMID:
29331635
5.
6.

Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes.

DeZern AE, Binder G, Ni Q, McGuire M, Smith BD.

Leuk Res. 2017 Dec;63:10-14. doi: 10.1016/j.leukres.2017.10.005. Epub 2017 Oct 18.

7.

Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Norsworthy KJ, DeZern AE, Tsai HL, Hand WA, Varadhan R, Gore SD, Gojo I, Pratz K, Carraway HE, Showel M, McDevitt MA, Gladstone D, Ghiaur G, Prince G, Seung AH, Benani D, Levis MJ, Karp JE, Smith BD.

Leuk Res. 2017 Oct;61:25-32. doi: 10.1016/j.leukres.2017.08.009. Epub 2017 Aug 30. Review.

8.

Single-Nucleotide Polymorphism Leading to False Allelic Fraction by Droplet Digital PCR.

Christenson ES, Dalton WB, Chu D, Waters I, Cravero K, Zabransky DJ, DeZern AE, Park BH.

Clin Chem. 2017 Aug;63(8):1370-1376. doi: 10.1373/clinchem.2017.273177. Epub 2017 Jun 14.

PMID:
28615231
9.

Paroxysmal nocturnal haemoglobinuria.

Hill A, DeZern AE, Kinoshita T, Brodsky RA.

Nat Rev Dis Primers. 2017 May 18;3:17028. doi: 10.1038/nrdp.2017.28. Review.

PMID:
28516949
10.

Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes.

DeZern AE, Binder G, Rizvi S, Corvino FA, Arikian SR, Surinach A, Lee J, Smith BD.

Leuk Lymphoma. 2017 Nov;58(11):2649-2656. doi: 10.1080/10428194.2017.1312372. Epub 2017 May 9.

PMID:
28482722
11.

Meaningful endpoints for therapies approved for hematologic malignancies.

Smith BD, DeZern AE, Bastian AW, Durie BGM.

Cancer. 2017 May 15;123(10):1689-1694. doi: 10.1002/cncr.30622. Epub 2017 Feb 21.

12.

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.

Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ.

Cancer. 2017 May 15;123(6):994-1002. doi: 10.1002/cncr.30533. Epub 2017 Jan 17.

13.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C.

J Natl Compr Canc Netw. 2017 Jan;15(1):60-87.

PMID:
28040720
14.

Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.

DeZern AE, Zahurak M, Symons H, Cooke K, Jones RJ, Brodsky RA.

Biol Blood Marrow Transplant. 2017 Mar;23(3):498-504. doi: 10.1016/j.bbmt.2016.12.628. Epub 2016 Dec 21.

15.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, Dezern AE, Huff CA, Borrello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Haematologica. 2017 Feb;102(2):391-400. doi: 10.3324/haematol.2016.144139. Epub 2016 Oct 20.

16.

Genetic panels in young patients with bone marrow failure: are they clinically relevant?

DeZern AE, Brodsky RA.

Haematologica. 2016 Nov;101(11):1275-1276. No abstract available.

17.

Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation.

Gladstone DE, Petri M, Bolaños-Meade J, Dezern AE, Jones RJ, Fine D, Brodsky RA.

Lupus. 2017 Jun;26(7):773-776. doi: 10.1177/0961203316669242. Epub 2016 Sep 30.

18.

Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).

DeZern AE, Zeidan AM, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, Sekeres MA; Evans MDS Clinical Research Consortium.

Leuk Lymphoma. 2017 Jun;58(6):1325-1331. doi: 10.1080/10428194.2016.1246726. Epub 2016 Oct 24.

19.

High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia.

Gamper CJ, Takemoto CM, Chen AR, Symons HJ, Loeb DM, Casella JF, Dezern AE, King KE, McGonigle AM, Jones RJ, Brodsky RA.

J Pediatr Hematol Oncol. 2016 Nov;38(8):627-635.

20.

Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema.

Stanley SE, Gable DL, Wagner CL, Carlile TM, Hanumanthu VS, Podlevsky JD, Khalil SE, DeZern AE, Rojas-Duran MF, Applegate CD, Alder JK, Parry EM, Gilbert WV, Armanios M.

Sci Transl Med. 2016 Aug 10;8(351):351ra107. doi: 10.1126/scitranslmed.aaf7837.

21.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

22.

Red blood cell transfusion triggers in acute leukemia: a randomized pilot study.

DeZern AE, Williams K, Zahurak M, Hand W, Stephens RS, King KE, Frank SM, Ness PM.

Transfusion. 2016 Jul;56(7):1750-7. doi: 10.1111/trf.13658. Epub 2016 May 20. Erratum in: Transfusion. 2016 Dec;56(12 ):3150.

23.

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.

Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA; MDS Clinical Research Consortium.

Haematologica. 2016 Jun;101(6):e224-7. doi: 10.3324/haematol.2015.140962. Epub 2016 Mar 18. No abstract available.

24.

Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.

Gondek LP, Zheng G, Ghiaur G, DeZern AE, Matsui W, Yegnasubramanian S, Lin MT, Levis M, Eshleman JR, Varadhan R, Tucker N, Jones R, Gocke CD.

Leukemia. 2016 Sep;30(9):1916-1920. doi: 10.1038/leu.2016.63. Epub 2016 Mar 15. No abstract available.

25.

Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders.

Klein OR, Chen AR, Gamper C, Loeb D, Zambidis E, Llosa N, Huo J, Dezern AE, Steppan D, Robey N, Holuba MJ, Cooke KR, Symons HJ.

Biol Blood Marrow Transplant. 2016 May;22(5):895-901. doi: 10.1016/j.bbmt.2016.02.001. Epub 2016 Feb 6.

26.

Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.

Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS; MDS Clinical Research Consortium.

Leuk Res. 2016 Feb;41:43-7. doi: 10.1016/j.leukres.2015.12.007. Epub 2015 Dec 22.

27.

Do somatic mutations in de novo MDS predict for response to treatment?

Schroeder MA, DeZern AE.

Hematology Am Soc Hematol Educ Program. 2015;2015:317-28. doi: 10.1182/asheducation-2015.1.317. Review.

PMID:
26637739
28.

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

DeZern AE.

Hematology Am Soc Hematol Educ Program. 2015;2015:308-16. doi: 10.1182/asheducation-2015.1.308.

PMID:
26637738
29.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Kasamon YL, Bolaños-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, Rosner GL, Brodsky RA, Perica K, Smith BD, Gladstone DE, Swinnen LJ, Showel MM, Matsui WH, Huff CA, Borrello I, Pratz KW, McDevitt MA, Gojo I, Dezern AE, Shanbhag S, Levis MJ, Luznik L, Ambinder RF, Fuchs EJ, Jones RJ.

J Clin Oncol. 2015 Oct 1;33(28):3152-61. doi: 10.1200/JCO.2014.60.4777. Epub 2015 Aug 10.

30.

Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders.

Gorgy AI, Jonassaint NL, Stanley SE, Koteish A, DeZern AE, Walter JE, Sopha SC, Hamilton JP, Hoover-Fong J, Chen AR, Anders RA, Kamel IR, Armanios M.

Chest. 2015 Oct;148(4):1019-1026. doi: 10.1378/chest.15-0825.

31.

Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

DeZern AE, Brodsky RA.

Hematol Oncol Clin North Am. 2015 Jun;29(3):479-94. doi: 10.1016/j.hoc.2015.01.005. Epub 2015 Mar 7. Review.

32.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL.

Blood. 2015 May 7;125(19):3024-31. doi: 10.1182/blood-2015-01-623991. Epub 2015 Mar 26.

33.

Myelodysplastic syndromes, version 2.2015.

Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Mar;13(3):261-72.

34.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Blood. 2014 Dec 11;124(25):3817-27. doi: 10.1182/blood-2014-07-587477. Epub 2014 Oct 14.

35.

Aplastic anemia in adolescents and young adults.

DeZern AE, Guinan EC.

Acta Haematol. 2014;132(3-4):331-9. doi: 10.1159/000360209. Epub 2014 Sep 10. Review.

36.

I walk the line: how to tell MDS from other bone marrow failure conditions.

Gondek LP, DeZern AE.

Curr Hematol Malig Rep. 2014 Dec;9(4):389-99. doi: 10.1007/s11899-014-0224-3.

37.

Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria.

DeZern AE, Uknis M, Yuan X, Mukhina GL, Varela J, Saye J, Pu J, Brodsky RA.

Exp Hematol. 2014 Oct;42(10):857-61.e1. doi: 10.1016/j.exphem.2014.06.007. Epub 2014 Jul 14.

38.

Risk-adjusted clinical outcomes in patients enrolled in a bloodless program.

Frank SM, Wick EC, Dezern AE, Ness PM, Wasey JO, Pippa AC, Dackiw E, Resar LM.

Transfusion. 2014 Oct;54(10 Pt 2):2668-77. doi: 10.1111/trf.12752. Epub 2014 Jun 18.

39.

The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure.

DeZern AE, Sekeres MA.

Oncologist. 2014 Jul;19(7):735-45. doi: 10.1634/theoncologist.2014-0056. Epub 2014 Jun 4. Review.

40.

Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes.

DeZern AE, Symons HJ, Resar LS, Borowitz MJ, Armanios MY, Brodsky RA.

Eur J Haematol. 2014 Jun;92(6):467-70. doi: 10.1111/ejh.12299. Epub 2014 Mar 18.

41.

Burst-forming unit-erythroid assays to distinguish cellular bone marrow failure disorders.

DeZern AE, Pu J, McDevitt MA, Jones RJ, Brodsky RA.

Exp Hematol. 2013 Sep;41(9):808-16. doi: 10.1016/j.exphem.2013.04.013. Epub 2013 May 6.

42.

Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases.

Dezern AE, Styler MJ, Drachman DB, Hummers LK, Jones RJ, Brodsky RA.

Am J Blood Res. 2013;3(1):84-90. Epub 2013 Jan 17.

43.

Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria.

DeZern AE, Dorr D, Brodsky RA.

Eur J Haematol. 2013 Jan;90(1):16-24. doi: 10.1111/ejh.12021. Epub 2012 Nov 22.

44.

Therapy for aplastic anemia.

DeZern AE, Guinan EC.

Hematology Am Soc Hematol Educ Program. 2011;2011:82-3. doi: 10.1182/asheducation-2011.1.82.

45.

Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy.

Gaillard S, Dinoso JB, Marsh JA, DeZern AE, O'Connell KA, Spivak AM, Alwood K, Durand CM, Ambinder RF, Blankson JN.

J Clin Virol. 2011 Jul;51(3):195-8. doi: 10.1016/j.jcv.2011.04.002. Epub 2011 May 7.

46.

Clinical management of aplastic anemia.

Dezern AE, Brodsky RA.

Expert Rev Hematol. 2011 Apr;4(2):221-30. doi: 10.1586/ehm.11.11. Review.

47.

High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.

DeZern AE, Petri M, Drachman DB, Kerr D, Hammond ER, Kowalski J, Tsai HL, Loeb DM, Anhalt G, Wigley F, Jones RJ, Brodsky RA.

Medicine (Baltimore). 2011 Mar;90(2):89-98. doi: 10.1097/MD.0b013e318210e685.

48.

Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.

DeZern AE, Sung A, Kim S, Smith BD, Karp JE, Gore SD, Jones RJ, Fuchs E, Luznik L, McDevitt M, Levis M.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1404-9. doi: 10.1016/j.bbmt.2011.02.003. Epub 2011 Feb 13.

49.

Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia.

Dezern AE, Luznik L, Fuchs EJ, Jones RJ, Brodsky RA.

Bone Marrow Transplant. 2011 Jul;46(7):1012-3. doi: 10.1038/bmt.2010.213. Epub 2010 Sep 13. No abstract available.

Supplemental Content

Loading ...
Support Center